SEC Form S-8 POS filed by Tectonic Therapeutic Inc.
As filed with the Securities and Exchange Commission on August 27, 2024
Registration No. 333-281690
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
to
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Tectonic Therapeutic, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 83-0710585 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
490 Arsenal Way Suite 210 Watertown, MA |
02472 | |
(Address of Principal Executive Offices) | (Zip Code) |
2019 Equity Incentive Plan
2024 Equity Incentive Plan
2024 Employee Stock Purchase Plan
(Full titles of the plans)
Daniel Lochner
Chief Financial Officer
490 Arsenal Way
Suite 210
Watertown, MA 02472
(339) 666-3320
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Marc A. Recht
Courtney T. Thorne
Katherine Denby
Cooley LLP
500 Boylston Street, 14th Floor
Boston, MA 02116
(617) 937-2300
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated Filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 (the “Amendment”), which relates to the Registration Statement filed on Form S-8, File No. 333-281690 (the “Original Registration Statement”) filed with the Securities and Exchange Commission on August 21, 2024 by Tectonic Therapeutic, Inc., a Delaware corporation (the “Registrant”), is being filed solely to file a Consent of Ernst & Young LLP, independent registered public accounting firm of AVROBIO, Inc. attached as Exhibit 23.2 hereto. Except as described herein, this Amendment does not update, amend or modify any other information, statement or disclosure contained in the Original Registration Statement, and all other portions of the Original Registration Statement, as previously filed, remain unchanged. No additional securities are to be registered, and registration fees were paid upon filing of the Original Registration Statement.
ITEM 8. | EXHIBITS. |
* | Filed herewith |
+ | Previously filed with the Original Registration Statement. |
1
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on August 27, 2024.
TECTONIC THERAPEUTIC, INC. | ||
By | /s/ Daniel Lochner | |
Daniel Lochner | ||
Chief Financial Officer |
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
* Alise Reicin |
President, Chief Executive Officer and Director (Principal Executive Officer) |
August 27, 2024 | ||
/s/ Daniel Lochner Daniel Lochner |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
August 27, 2024 | ||
* Terrance McGuire |
Director |
August 27, 2024 | ||
* Stefan Vitorovic |
Director |
August 27, 2024 | ||
* Timothy A. Springer |
Director |
August 27, 2024 | ||
* Praveen Tipirneni |
Director |
August 27, 2024 | ||
* Phillip B. Donenberg |
Director |
August 27, 2024 |
*By: | /s/ Daniel Lochner | |
Daniel Lochner | ||
Attorney-in-Fact |
2